+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Global Oncology Based Molecular Diagnostics Market Size, Share & Trends Analysis Report by Type (Breast Cancer, Lung Cancer), Product (Instruments, Reagents), Technology (PCR, Sequencing), Region, and Segment Forecasts, 2023-2030

  • PDF Icon

    Report

  • 139 Pages
  • November 2023
  • Region: Global
  • Grand View Research
  • ID: 5914578
Description Jump to:
The global oncology based molecular diagnostics market size is expected to reach USD 6.00 billion by 2030, registering a CAGR of 12.1% from 2023 to 2030, according to the report. The rising geriatric population base, increasing global prevalence of cancer, rise in sedentary lifestyle adoption levels, and rising awareness & patient education are the driving forces for the oncology based molecular diagnostics market growth over the forecast period.

Growing prevalence of cancer patients owing to adoption of sedentary lifestyles and decrease in immunity levels are estimated to increase industrial growth rate. Furthermore, large variations in both cancer incidence and mortality rates in different sub-regions of developing countries such as Brazil, Mexico, South Africa, and India are also anticipated to enhance the usage of molecular diagnostics to increase survival rates by early detection and validation.

Oncology Based Molecular Diagnostics Market Report Highlights

  • Breast cancer dominated the overall market in 2022 in terms of revenue share due to large test volumes and an extensive portfolio of commercialized products.
  • Colorectal cancer is estimated to witness lucrative growth over the forecast period owing to the availability of technologically advanced microarrays & assays such as miRNA microarrays.
  • On the basis of product, the reagents segment held the highest share of almost 58.0% of the overall revenue in 2022. Growing initiatives by researchers in this field for detection of disease related novel biomarkers for drug development purpose are estimated to be the key factors attributing to this segment’s growth
  • The polymerase chain reaction (PCR) technology segment held the highest revenue share of 31% in 2022. This can be attributed to its growing utilization in research labs and the increased need for enhanced diagnostics.
  • The sequencing segment is anticipated to witness a significant growth rate of 14.3% during the forecast period. Development of next generation sequencing techniques providing high throughput analysis and sequencing of genomic data is one of the key drivers for significant growth.
  • North America dominated the market with a revenue share of over 40% in 2022 The strong market growth in this region can be attributed to a well-established healthcare infrastructure, the constantly rising health-conscious population base, and high healthcare expenditure.
  • Asia Pacific region is expected to advance at the fastest CAGR of 15.8% during the projection period owing to the presence of a large number of target population, rising awareness levels for cancer detection, and increasing government initiatives in this region enabling the achievement of the largest market share


This product will be delivered within 2 business days.

Table of Contents

Chapter 1. Methodology and Scope
1.1. Market Segmentation & Scope
1.1.1. Type
1.1.2. Product
1.1.3. Technology
1.1.4. Regional scope
1.1.5. Estimates and forecast timeline
1.2. Research Methodology
1.3. Information Procurement
1.3.1. Purchased database
1.3.2. Internal database
1.3.3. Secondary sources
1.3.4. Primary research
1.3.5. Details of primary research
1.4. Information or Data Analysis
1.4.1. Data analysis models
1.5. Market Formulation & Validation
1.6. Model Details
1.7. List of Secondary Sources
1.8. List of Primary Sources
1.9. Objectives
1.9.1. Objective 1
1.9.2. Objective 2
Chapter 2. Executive Summary
2.1. Market Outlook
2.2. Segment Outlook
2.2.1. Type outlook
2.2.2. Product outlook
2.2.3. Technology outlook
2.2.4. Regional outlook
2.3. Competitive Insights
Chapter 3. Oncology Based Molecular Diagnostics Market Variables, Trends & Scope
3.1. Market Lineage Outlook
3.1.1. Parent Market Outlook
3.1.2. Related/Ancillary Market outlook
3.2. Penetration & Growth Prospect Mapping
3.3. Market Dynamics
3.3.1. Market Driver Analysis
3.3.2. Market Restraint Analysis
3.4. Oncology Based Molecular Diagnostics Market Analysis Tools
3.4.1. Industry Analysis - Porter’s Five Forces
3.4.1.1. Supplier power
3.4.1.2. Buyer power
3.4.1.3. Substitution threat
3.4.1.4. Threat of new entrant
3.4.1.5. Competitive rivalry
3.4.2. PESTEL Analysis
3.4.2.1. Political landscape
3.4.2.2. Technological landscape
3.4.2.3. Economic landscape
Chapter 4. Oncology Based Molecular Diagnostics Market: Type Estimates & Trend Analysis
4.1. Oncology Based Molecular Diagnostics Market: Key Takeaways
4.2. Oncology Based Molecular Diagnostics Market: Type Movement & Market Share Analysis, 2022 & 2030
4.3. Breast Cancer
4.3.1. Breast cancer market estimates and forecasts, 2018 to 2030 (USD Million)
4.4. Prostate Cancer
4.4.1. Prostate cancer market estimates and forecasts, 2018 to 2030 (USD Million)
4.5. Colorectal Cancer
4.5.1. Colorectal cancer market estimates and forecasts, 2018 to 2030 (USD Million)
4.6. Cervical Cancer
4.6.1. Cervical cancer market estimates and forecasts, 2018 to 2030 (USD Million)
4.7. Liver Cancer
4.7.1. Liver cancer market estimates and forecasts, 2018 to 2030 (USD Million)
4.8. Lung Cancer
4.8.1. Lung cancer market estimates and forecasts, 2018 to 2030 (USD Million)
4.9. Blood Cancer
4.9.1. Blood cancer market estimates and forecasts, 2018 to 2030 (USD Million)
4.10. Kidney Cancer
4.10.1. Kidney cancer market estimates and forecasts, 2018 to 2030 (USD Million)
4.11. Other Cancer
4.11.1. Others cancer market estimates and forecasts, 2018 to 2030 (USD Million)
Chapter 5. Oncology Based Molecular Diagnostics Market: Product Estimates & Trend Analysis
5.1. Oncology Based Molecular Diagnostics Market: Key Takeaways
5.2. Oncology Based Molecular Diagnostics Market: Product Movement & Market Share Analysis, 2022 & 2030
5.3. Instruments
5.3.1. Instruments market estimates and forecasts, 2018 to 2030 (USD Million)
5.4. Reagents
5.4.1. Reagents market estimates and forecasts, 2018 to 2030 (USD Million)
5.5. Others
5.5.1. Other products market estimates and forecasts, 2018 to 2030 (USD Million)
Chapter 6. Oncology Based Molecular Diagnostics Market: Technology Estimates & Trend Analysis
6.1. Oncology Based Molecular Diagnostics Market: Key Takeaways
6.2. Oncology Based Molecular Diagnostics Market: Technology Movement & Market Share Analysis, 2022 & 2030
6.3. PCR
6.3.1. PCR market estimates and forecasts, 2018 to 2030 (USD Million)
6.4. In situ hybridization
6.4.1. In situ hybridization market estimates and forecasts, 2018 to 2030 (USD Million)
6.5. INAAT
6.5.1. INAAT market estimates and forecasts, 2018 to 2030 (USD Million)
6.6. Chips and microarrays
6.6.1. Chips and microarrays market estimates and forecasts, 2018 to 2030 (USD Million)
6.7. Mass spectrometry
6.7.1. Mass spectrometry market estimates and forecasts, 2018 to 2030 (USD Million)
6.8. Sequencing
6.8.1. Sequencing market estimates and forecasts, 2018 to 2030 (USD Million)
6.9. TMA
6.9.1. TMA market estimates and forecasts, 2018 to 2030 (USD Million)
6.10. Others
6.10.1. Others market estimates and forecasts, 2018 to 2030 (USD Million)
Chapter 7. Oncology Based Molecular Diagnostics Market: Regional Estimates & Trend Analysis
7.1. Regional Outlook
7.2. Oncology Based Molecular Diagnostics Market by Region: Key Takeaways
7.3. North America
7.3.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
7.3.2. U.S.
7.3.2.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
7.3.3. Canada
7.3.3.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
7.4. Europe
7.4.1. U.K.
7.4.1.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
7.4.2. Germany
7.4.2.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
7.4.3. France
7.4.3.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
7.4.4. Italy
7.4.4.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
7.4.5. Spain
7.4.5.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
7.4.6. Sweden
7.4.6.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
7.4.7. Norway
7.4.7.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
7.4.8. Denmark
7.4.8.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
7.5. Asia Pacific
7.5.1. Japan
7.5.1.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
7.5.2. China
7.5.2.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
7.5.3. India
7.5.3.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
7.5.4. Australia
7.5.4.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
7.5.5. Thailand
7.5.5.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
7.5.6. South Korea
7.5.6.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
7.6. Latin America
7.6.1. Brazil
7.6.1.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
7.6.2. Mexico
7.6.2.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
7.6.3. Argentina
7.6.3.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
7.7. MEA
7.7.1. Saudi Arabia
7.7.1.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
7.7.2. South Africa
7.7.2.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
7.7.3. UAE
7.7.3.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
7.7.4. Kuwait
7.7.4.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
Chapter 8. Competitive Landscape
8.1. Recent Developments & Impact Analysis, By Key Market Participants
8.2. Company/Competition Categorization
8.2.1. Abbott
8.2.1.1. Company overview
8.2.1.2. Financial performance
8.2.1.3. Product benchmarking
8.2.1.4. Strategic initiatives
8.2.2. Bayer AG
8.2.2.1. Company overview
8.2.2.2. Financial performance
8.2.2.3. Product benchmarking
8.2.2.4. Strategic initiatives
8.2.3. BD
8.2.3.1. Company overview
8.2.3.2. Financial performance
8.2.3.3. Product benchmarking
8.2.3.4. Strategic initiatives
8.2.4. Cepheid
8.2.4.1. Company overview
8.2.4.2. Financial performance
8.2.4.3. Product benchmarking
8.2.4.4. Strategic initiatives
8.2.5. Agilent Technologies, Inc.
8.2.5.1. Company overview
8.2.5.2. Financial performance
8.2.5.3. Product benchmarking
8.2.5.4. Strategic initiatives
8.2.6. Danaher
8.2.6.1. Company overview
8.2.6.2. Financial performance
8.2.6.3. Product benchmarking
8.2.6.4. Strategic initiatives
8.2.7. Hologic, Inc.
8.2.7.1. Company overview
8.2.7.2. Financial performance
8.2.7.3. Product benchmarking
8.2.7.4. Strategic initiatives
8.2.8. Qiagen
8.2.8.1. Company overview
8.2.8.2. Financial performance
8.2.8.3. Product benchmarking
8.2.8.4. Strategic initiatives
8.2.9. F. Hoffmann-La Roche Ltd.
8.2.9.1. Company overview
8.2.9.2. Financial performance
8.2.9.3. Product benchmarking
8.2.9.4. Strategic initiatives
8.2.10. Siemens
8.2.10.1. Company overview
8.2.10.2. Financial performance
8.2.10.3. Product benchmarking
8.2.10.4. Strategic initiatives
8.2.11. Sysmex
8.2.11.1. Company overview
8.2.11.2. Financial performance
8.2.11.3. Product benchmarking
8.2.11.4. Strategic initiatives
List of Tables
Table 1 List of Abbreviations
Table 2 North America Oncology Based Molecular Diagnostics Market, by Type, 2018 - 2030 (USD Million)
Table 3 North America Oncology Based Molecular Diagnostics Market, by Product, 2018 - 2030 (USD Million)
Table 4 North America Oncology Based Molecular Diagnostics Market, by Technology, 2018 - 2030 (USD Million)
Table 5 North America Oncology Based Molecular Diagnostics Market, by Region, 2018 - 2030 (USD Million)
Table 6 U.S. Oncology Based Molecular Diagnostics Market, by Type, 2018 - 2030 (USD Million)
Table 7 U.S. Oncology Based Molecular Diagnostics Market, by Product, 2018 - 2030 (USD Million)
Table 8 U.S. Oncology Based Molecular Diagnostics Market, by Technology, 2018 - 2030 (USD Million)
Table 9 Canada Oncology Based Molecular Diagnostics Market, by Type, 2018 - 2030 (USD Million)
Table 10 Canada Oncology Based Molecular Diagnostics Market, by Product, 2018 - 2030 (USD Million)
Table 11 Canada Oncology Based Molecular Diagnostics Market, by Technology, 2018 - 2030 (USD Million)
Table 12 Europe Oncology Based Molecular Diagnostics Market, by Type, 2018 - 2030 (USD Million)
Table 13 Europe Oncology Based Molecular Diagnostics Market, by Product, 2018 - 2030 (USD Million)
Table 14 Europe Oncology Based Molecular Diagnostics Market, by Technology, 2018 - 2030 (USD Million)
Table 15 Europe Oncology Based Molecular Diagnostics Market, by Region, 2018 - 2030 (USD Million)
Table 16 Germany Oncology Based Molecular Diagnostics Market, by Type, 2018 - 2030 (USD Million)
Table 17 Germany Oncology Based Molecular Diagnostics Market, by Product, 2018 - 2030 (USD Million)
Table 18 Germany Oncology Based Molecular Diagnostics Market, by Technology, 2018 - 2030 (USD Million)
Table 19 UK Oncology Based Molecular Diagnostics Market, by Type, 2018 - 2030 (USD Million)
Table 20 UK Oncology Based Molecular Diagnostics Market, by Product, 2018 - 2030 (USD Million)
Table 21 UK Oncology Based Molecular Diagnostics Market, by Technology, 2018 - 2030 (USD Million)
Table 22 France Oncology Based Molecular Diagnostics Market, by Type, 2018 - 2030 (USD Million)
Table 23 France Oncology Based Molecular Diagnostics Market, by Product, 2018 - 2030 (USD Million)
Table 24 France Oncology Based Molecular Diagnostics Market, by Technology, 2018 - 2030 (USD Million)
Table 25 Italy Oncology Based Molecular Diagnostics Market, by Type, 2018 - 2030 (USD Million)
Table 26 Italy Oncology Based Molecular Diagnostics Market, by Product, 2018 - 2030 (USD Million)
Table 27 Italy Oncology Based Molecular Diagnostics Market, by Technology, 2018 - 2030 (USD Million)
Table 28 Spain Oncology Based Molecular Diagnostics Market, by Type, 2018 - 2030 (USD Million)
Table 29 Spain Oncology Based Molecular Diagnostics Market, by Product, 2018 - 2030 (USD Million)
Table 30 Spain Oncology Based Molecular Diagnostics Market, by Technology, 2018 - 2030 (USD Million)
Table 31 Sweden Oncology Based Molecular Diagnostics Market, by Type, 2018 - 2030 (USD Million)
Table 32 Sweden Oncology Based Molecular Diagnostics Market, by Product, 2018 - 2030 (USD Million)
Table 33 Sweden Oncology Based Molecular Diagnostics Market, by Technology, 2018 - 2030 (USD Million)
Table 34 Norway Oncology Based Molecular Diagnostics Market, by Type, 2018 - 2030 (USD Million)
Table 35 Norway Oncology Based Molecular Diagnostics Market, by Product, 2018 - 2030 (USD Million)
Table 36 Norway Oncology Based Molecular Diagnostics Market, by Technology, 2018 - 2030 (USD Million)
Table 37 Denmark Oncology Based Molecular Diagnostics Market, by Type, 2018 - 2030 (USD Million)
Table 38 Denmark Oncology Based Molecular Diagnostics Market, by Product, 2018 - 2030 (USD Million)
Table 39 Denmark Oncology Based Molecular Diagnostics Market, by Technology, 2018 - 2030 (USD Million)
Table 40 Asia Pacific Oncology Based Molecular Diagnostics Market, by Type, 2018 - 2030 (USD Million)
Table 41 Asia Pacific Oncology Based Molecular Diagnostics Market, by Product, 2018 - 2030 (USD Million)
Table 42 Asia Pacific Oncology Based Molecular Diagnostics Market, by Technology, 2018 - 2030 (USD Million)
Table 43 Asia Pacific Oncology Based Molecular Diagnostics Market, by Region, 2018 - 2030 (USD Million)
Table 44 China Oncology Based Molecular Diagnostics Market, by Type, 2018 - 2030 (USD Million)
Table 45 China Oncology Based Molecular Diagnostics Market, by Product, 2018 - 2030 (USD Million)
Table 46 China Oncology Based Molecular Diagnostics Market, by Technology, 2018 - 2030 (USD Million)
Table 47 Japan Oncology Based Molecular Diagnostics Market, by Type, 2018 - 2030 (USD Million)
Table 48 Japan Oncology Based Molecular Diagnostics Market, by Product, 2018 - 2030 (USD Million)
Table 49 Japan Oncology Based Molecular Diagnostics Market, by Technology, 2018 - 2030 (USD Million)
Table 50 India Oncology Based Molecular Diagnostics Market, by Type, 2018 - 2030 (USD Million)
Table 51 India Oncology Based Molecular Diagnostics Market, by Product, 2018 - 2030 (USD Million)
Table 52 India Oncology Based Molecular Diagnostics Market, by Technology, 2018 - 2030 (USD Million)
Table 53 Thailand Oncology Based Molecular Diagnostics Market, by Type, 2018 - 2030 (USD Million)
Table 54 Thailand Oncology Based Molecular Diagnostics Market, by Product, 2018 - 2030 (USD Million)
Table 55 Thailand Oncology Based Molecular Diagnostics Market, by Technology, 2018 - 2030 (USD Million)
Table 56 South Korea Oncology Based Molecular Diagnostics Market, by Type, 2018 - 2030 (USD Million)
Table 57 South Korea Oncology Based Molecular Diagnostics Market, by Product, 2018 - 2030 (USD Million)
Table 58 South Korea Oncology Based Molecular Diagnostics Market, by Technology, 2018 - 2030 (USD Million)
Table 59 Australia Oncology Based Molecular Diagnostics Market, by Type, 2018 - 2030 (USD Million)
Table 60 Australia Oncology Based Molecular Diagnostics Market, by Product, 2018 - 2030 (USD Million)
Table 61 Australia Oncology Based Molecular Diagnostics Market, by Technology, 2018 - 2030 (USD Million)
Table 62 Latin America Oncology Based Molecular Diagnostics Market, by Type, 2018 - 2030 (USD Million)
Table 63 Latin America Oncology Based Molecular Diagnostics Market, by Product, 2018 - 2030 (USD Million)
Table 64 Latin America Oncology Based Molecular Diagnostics Market, by Technology, 2018 - 2030 (USD Million)
Table 65 Latin America Oncology Based Molecular Diagnostics Market, by Region, 2018 - 2030 (USD Million)
Table 66 Brazil Oncology Based Molecular Diagnostics Market, by Type, 2018 - 2030 (USD Million)
Table 67 Brazil Oncology Based Molecular Diagnostics Market, by Product, 2018 - 2030 (USD Million)
Table 68 Brazil Oncology Based Molecular Diagnostics Market, by Technology, 2018 - 2030 (USD Million)
Table 69 Mexico Oncology Based Molecular Diagnostics Market, by Type, 2018 - 2030 (USD Million)
Table 70 Mexico Oncology Based Molecular Diagnostics Market, by Product, 2018 - 2030 (USD Million)
Table 71 Mexico Oncology Based Molecular Diagnostics Market, by Technology, 2018 - 2030 (USD Million)
Table 72 Argentina Oncology Based Molecular Diagnostics Market, by Type, 2018 - 2030 (USD Million)
Table 73 Argentina Oncology Based Molecular Diagnostics Market, by Product, 2018 - 2030 (USD Million)
Table 74 Argentina Oncology Based Molecular Diagnostics Market, by Technology, 2018 - 2030 (USD Million)
Table 75 Middle East and Africa Oncology Based Molecular Diagnostics Market, by Type, 2018 - 2030 (USD Million)
Table 76 Middle East and Africa Oncology Based Molecular Diagnostics Market, by Product, 2018 - 2030 (USD Million)
Table 77 Middle East and Africa Oncology Based Molecular Diagnostics Market, by Technology, 2018 - 2030 (USD Million)
Table 78 Middle East and Africa Oncology Based Molecular Diagnostics Market, by Region, 2018 - 2030 (USD Million)
Table 79 South Africa Oncology Based Molecular Diagnostics Market, by Type, 2018 - 2030 (USD Million)
Table 80 South Africa Oncology Based Molecular Diagnostics Market, by Product, 2018 - 2030 (USD Million)
Table 81 South Africa Oncology Based Molecular Diagnostics Market, by Technology, 2018 - 2030 (USD Million)
Table 82 Saudi Arabia Oncology Based Molecular Diagnostics Market, by Type, 2018 - 2030 (USD Million)
Table 83 Saudi Arabia Oncology Based Molecular Diagnostics Market, by Product, 2018 - 2030 (USD Million)
Table 84 Saudi Arabia Oncology Based Molecular Diagnostics Market, by Technology, 2018 - 2030 (USD Million)
Table 85 UAE Oncology Based Molecular Diagnostics Market, by Type, 2018 - 2030 (USD Million)
Table 86 UAE Oncology Based Molecular Diagnostics Market, by Product, 2018 - 2030 (USD Million)
Table 87 UAE Oncology Based Molecular Diagnostics Market, by Technology, 2018 - 2030 (USD Million)
Table 88 Kuwait Oncology Based Molecular Diagnostics Market, by Type, 2018 - 2030 (USD Million)
Table 89 Kuwait Oncology Based Molecular Diagnostics Market, by Product, 2018 - 2030 (USD Million)
Table 90 Kuwait Oncology Based Molecular Diagnostics Market, by Technology, 2018 - 2030 (USD Million)
List of Figures
Fig. 1 Market research process
Fig. 2 Data triangulation techniques
Fig. 3 Primary research pattern
Fig. 4 Market research approaches
Fig. 5 Value-chain-based sizing & forecasting
Fig. 6 QFD modeling for market share assessment
Fig. 7 Market formulation & validation
Fig. 8 Oncology based molecular diagnostics market: market outlook
Fig. 9 Oncology based molecular diagnostics market competitive insights
Fig. 10 Parent market outlook
Fig. 11 Related/ancillary market outlook
Fig. 12 Penetration and growth prospect mapping
Fig. 13 Industry value chain analysis
Fig. 14 Oncology based molecular diagnostics market driver impact
Fig. 15 Oncology based molecular diagnostics market restraint impact
Fig. 16 Oncology based molecular diagnostics market strategic initiatives analysis
Fig. 17 Oncology based molecular diagnostics market: type movement analysis
Fig. 18 Oncology based molecular diagnostics market: type outlook and key takeaways
Fig. 19 Breast cancer market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 20 Prostate cancer market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 21 Colorectal cancer market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 22 Cervical cancer market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 23 Liver cancer market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 24 Lung cancer market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 25 Blood cancer market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 26 Kidney cancer market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 27 Other cancer market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 28 Oncology based molecular diagnostics market: product movement analysis
Fig. 29 Oncology based molecular diagnostics market: product outlook and key takeaways
Fig. 30 Instruments market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 31 Reagents market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 32 Others market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 33 Oncology based molecular diagnostics market: technology movement analysis
Fig. 34 Oncology based molecular diagnostics market: technology outlook and key takeaways
Fig. 35 PCR market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 36 In Situ Hybridization market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 37 INAAT market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 38 Chips and microarrays market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 39 Mass spectrometry market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 40 Sequencing market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 41 TMA market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 42 Others market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 43 Global oncology based molecular diagnostics market: regional movement analysis
Fig. 44 Global oncology based molecular diagnostics market: regional outlook and key takeaways
Fig. 45 North America market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 46 U.S. market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 47 Canada market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 48 Europe market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 49 UK market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 50 Germany market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 51 France market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 52 Italy market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 53 Spain market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 54 Sweden market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 55 Norway market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 56 Denmark market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 57 Asia Pacific market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 58 Japan market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 59 China market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 60 India market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 61 Australia market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 62 Thailand market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 63 South Korea market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 64 Latin America market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 65 Brazil market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 66 Mexico market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 67 Argentina market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 68 Middle East and Africa market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 69 Saudi Arabia market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 70 South Africa market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 71 UAE market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 72 Kuwait market estimates and forecasts, 2018 - 2030 (USD Million)

Companies Profiled

  • Abbott
  • Bayer AG
  • BD
  • Cepheid
  • Agilent Technologies, Inc.
  • Danaher
  • Hologic, Inc.
  • Qiagen
  • F. Hoffmann-La Roche Ltd.
  • Siemens
  • Sysmex

Methodology

Loading
LOADING...

Table Information

Report AttributeDetails
No. of Pages139
PublishedNovember 2023
Forecast Period2022 - 2030
Estimated Market Value ( USD ) in 2022 $ 2.44 Billion
Forecasted Market Value ( USD ) by 2030 $ 6 Billion
Compound Annual Growth Rate12.1%
Regions CoveredGlobal
No. of Companies Mentioned11

Related Topics

Related Reports

Global Molecular Diagnostics Market Size, Share & Trends Analysis Report by Product (Reagents, Instruments), Technology (PCR, INAAT), Application (Oncology, Genetic Testing), Test Location, and Segment Forecasts, 2024-2030 - Product Image

Global Molecular Diagnostics Market Size, Share & Trends Analysis Report by Product (Reagents, Instruments), Technology (PCR, INAAT), Application (Oncology, Genetic Testing), Test Location, and Segment Forecasts, 2024-2030

  • Report
  • 270 Pages
  • Global
From
Molecular Diagnostics Market by Product & Service (Reagents, Kits), Test Type (Lab, PoC), Sample Type (Blood, Urine), Technology (PCR, INAAT), Application (Infectious, Oncology), End User (Diagnostic Labs, Hospitals), Region - Global Forecast to 2028 - Product Image

Molecular Diagnostics Market by Product & Service (Reagents, Kits), Test Type (Lab, PoC), Sample Type (Blood, Urine), Technology (PCR, INAAT), Application (Infectious, Oncology), End User (Diagnostic Labs, Hospitals), Region - Global Forecast to 2028

  • Report
  • 310 Pages
  • Global
From
Nucleic Acid Amplification Testing Market Size, Share & Trends Analysis Report By Type (PCR, INAAT), By Application (Infectious Disease Testing, Oncology Testing), By End-use, By Region, And Segment Forecasts, 2023 - 2030 - Product Image

Nucleic Acid Amplification Testing Market Size, Share & Trends Analysis Report By Type (PCR, INAAT), By Application (Infectious Disease Testing, Oncology Testing), By End-use, By Region, And Segment Forecasts, 2023 - 2030

  • Report
  • 120 Pages
  • Global
From
In-Vitro Diagnostics Market by Offering (Kits, Software), Technology (Immunoassay, Molecular Diagnostics [PCR, NGS, Microarray], Rapid Tests, Biochemistry), Application (Infectious Diseases, Oncology), Diagnostic Approach (Lab, POC) - Global Forecast to 2030 - Product Image

In-Vitro Diagnostics Market by Offering (Kits, Software), Technology (Immunoassay, Molecular Diagnostics [PCR, NGS, Microarray], Rapid Tests, Biochemistry), Application (Infectious Diseases, Oncology), Diagnostic Approach (Lab, POC) - Global Forecast to 2030

  • Report
  • 526 Pages
  • Global
From
Global Pharmacogenomics Market by Offering (Instrument, Consumables, Software), Technology (PCR, Sequencing, Microarray), Application (Oncology, Mental Health, Cardiology, Neurology, Infectious Disease), End User (Hospitals, Academic) - Forecast to 2031 - Product Image

Global Pharmacogenomics Market by Offering (Instrument, Consumables, Software), Technology (PCR, Sequencing, Microarray), Application (Oncology, Mental Health, Cardiology, Neurology, Infectious Disease), End User (Hospitals, Academic) - Forecast to 2031

  • Report
  • 210 Pages
  • Global
From

About the Oncology Based Molecular Diagnostics Market

The Oncology Based Molecular Diagnostics market intersects with the field of genomics to enhance the understanding and treatment of cancer. Molecular diagnostics involves analyzing biological markers in the genome and proteome by applying molecular biology to medical testing. In oncology, these diagnostic tools help to detect specific genetic mutations, epigenetic changes, and patterns of gene expression that are characteristic of different cancers. This information is then used for various purposes including cancer detection, prognostication, and the personalization of therapy. Advancements in genomic technologies have fostered the development of highly sensitive and specific tests capable of detecting minute amounts of cancer-related genetic material, even from circulating tumor cells or cell-free DNA. These innovations have made it possible for earlier detection, improved monitoring of treatment response, and the identification of potential therapeutic targets, thus contributing to precision medicine in oncology. Several companies operate within the Oncology Based Molecular Diagnostics market, harnessing genomic advancements to offer a range of services and products. Notable players include Illumina, Inc., known for their sequencing and array-based technologies for genomics analysis; Roche Molecular Diagnostics, part of the Roche Group, offering a variety of cancer-related diagnostic tools; Agilent Technologies, specializing in diagnostics including genomic analysis equipment and software; Thermo Fisher Scientific, which provides instruments, reagents, and software for molecular diagnostics; and Myriad Genetics, which offers predictive cancer testing and personalized medicine. These companies, among others, contribute to the development and application of molecular diagnostic technologies Show Less Read more

Copyright © 2002-2024 Research and Markets. All Rights Reserved.